Molecular Partners AG ADR (MOLN) — Titan Protect Analysis

MOLN

Molecular Partners AG ADR

Healthcare · ·

$4.10

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$147M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-14.24

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-59.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.86

+189% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Molecular Partners AG ADR

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting t

https://www.molecularpartners.com

Country: Switzerland Employees: 134 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.371

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0493

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.045

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-3.1%

Historical annualised return based on price data

Max Drawdown

-68.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

122

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.74

Less volatile than the market — more defensive

52W High

$5.36

24% below the year high

52W Low

$3.41

20% above the year low

Avg Volume

4,236

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.98

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

4.89

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-25,200,500

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-58,024,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$16.81

Target Median

$11.86

Target Low

$3.74

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go